Abstract: The present invention discloses an isogeometric analysis method based on a geometric reconstruction model comprising steps of: dividing boundaries of a CAD model into triangular patches or directly based on point cloud data, generating a closed regular embedded domain, dividing the embedded domain into regular sub-domains, dividing the elements according to a positional relationship between the boundaries of the triangular patches/points and the elements into trimmed elements and untrimmed elements; calculating a minimum directional distance from each vertex of a trimmed element to a triangular patch near the trimmed element; using the minimum directional distance to divide the untrimmed elements into real and virtual elements; using the minimum directional distance as a level set function value, and using a marching tetrahedra algorithm to reconstruct a displayed geometric model based on the regular embedded domain; after obtaining the level set function value, calculating the level set function value of a G

Abstract: Salts of dihydropyrimidine derivatives, complexes and uses thereof in medicine, and complexes and pharmaceutical compositions thereof. The uses of the addition salts, the complexes or the pharmaceutical compositions in the manufacture of a medicament, especially in the manufacture of a medicament for preventing, managing, treating or lessening hepatitis B virus (HBV) infection.

Abstract: A preparation method of substituted pyrimidine piperazine compounds, as well as intermediate compounds used in the method. The preparation method has the advantages of cheap and easily available raw materials, mild conditions, short reaction time, safety and controllability, high total yield, which is especially suitable for industrial production.

Abstract: This application discloses a method for switching an execution environment and a related device thereof, to effectively prevent a hacker from maliciously accessing a TEE through ATF. The method in this application includes: After writing a first virtual address into a return address register of the TEE, the ATF determines whether the first virtual address is within a valid address range, and switches to the TEE based on the first virtual address only when determining that the first virtual address is within the valid address range.

Abstract: A ROR?t inhibitor as well as a preparation method thereof and uses thereof, and a pharmaceutical composition including the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in the treatment or prevention of ROR?t-mediated cancer, inflammation, or autoimmune diseases in mammals, especially humans.

Abstract: An ROR?t inhibitor, a preparation method thereof and uses thereof. The invention also relates to a pharmaceutical composition of the compound, a method for preparing the pharmaceutical composition, and use of the compound or the pharmaceutical composition in treating or preventing cancer, inflammation, or autoimmune diseases mediated by ROR?t in mammals.

Abstract: A fused tetracyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. A compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B, wherein each variable is as defined in the specification.

Abstract: Pharmaceuticals, and specifically a Teixobactin analogue and use thereof. A pharmaceutical composition having the compound and use of the compound and the pharmaceutical composition thereof inhibits the growth and/or reproduction of Gram-positive bacteria or Mycobacterium tuberculosis.

Abstract: Thienopyrimidine derivative having stereo configurations and use thereof in medicine. Also included are pharmaceutical compositions of the compounds. The compounds or pharmaceutical compositions may be used to inhibit acetyl-CoA carboxylase (ACC). A method for preparing the compounds and the pharmaceutical compositions, and use thereof in treatment or prevention of diseases associated with ACC regulation of mammals, in particular, humans.

Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.

Abstract: A pyrrole amide compound, a pharmaceutical composition thereof and use thereof. The compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.

Abstract: A dihydropyrimidine compound and application thereof as a drug, in particular, application as a drug for treating and preventing hepatitis B. Specifically, a compound represented by general formula (I) or (Ia) or a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein variables are as defined in the description. Use of the compound represented by general formula (I) or (Ia) or the stereoisomer, the tautomer, the oxynitride, the solvate, the metabolite, or the pharmaceutically acceptable salt thereof as a drug, in particular use as a drug for treating and preventing hepatitis B.

Abstract: A RET inhibitor, a pharmaceutical composition thereof and uses thereof including a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Furthermore, a pharmaceutical composition including the compound, and uses of the compound and pharmaceutical composition thereof in the manufacture of a medicament for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Abstract: A RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, the present invention provides a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The invention also relates to a pharmaceutical composition including the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.

Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Abstract: Disclosed are a sesquiterpene derivative and a use of the same in preparation of a medicament for treating hepatitis B diseases. The sesquiterpene derivative has the effects of down-regulating the hepatocyte nuclear factor 4? (HNF-4?) and significantly inhibiting the hepatitis B virus, and can be used for preventing and/or treating and/or assisting in the treatment of liver system diseases and symptoms caused by the hepatitis B virus, and can be used as a hepatic protective agent. In addition, the synthetic sesquiterpene derivative can also be used for preventing or treating viral infectious diseases and conditions resulting from the influenza virus, coxsackievirus, herpes simplex virus, etc. Also involved is the preparation of the synthetic sesquiterpene derivative, which acts as a raw material, in clinically acceptable pharmaceutical formulations, such as oral dosage forms such as tablets, capsules and drop pills or non-oral dosage forms such as inhalants and injections.

Abstract: A fused tetracyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. A compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B, wherein each variable is as defined in the specification.

Abstract: A class of fluorine-substituted indazole compounds and uses thereof having the general formula depicted below in which C1 is where is the bond through which C1 is attached to L, and C2 is where is the bond through which C2 is attached to indazole, and pharmaceutical compositions containing these compounds. The compounds and pharmaceutical compositions of the invention can be used as soluble guanylate cyclase simulators.

Abstract: A pyrrolidineamide derivatives and uses thereof, specifically, the present invention relates to a novel pyrrolidineamide compound and a pharmaceutical composition containing this compound, which can be used as a MAO-B inhibitor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a disease regulated by MAO-B comprising a neurodegenerative disease, especially Parkinson's disease.